Congress backs drug price cap tied to lowest international rates
H.Res. 928 — Affirming support for most-favored-Nation drug pricing for United States patients. · Filed by Debbie Dingell (D-MI) · 1 cosponsor · Introduced Dec 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution expresses House support for 'most-favored-nation' drug pricing—a policy that would cap U.S. prescription drug prices at the lowest prices charged in other developed countries. It cites data showing Americans pay 2.78 times more for drugs than comparable nations and endorses President Trump's May 2025 executive order directing the administration to align U.S. drug prices with those in peer countries.
Why we flagged it
This is a non-binding resolution expressing congressional support for most-favored-nation drug pricing and Medicare negotiation as mechanisms to reduce prescription drug costs for U.S. patients. It is a messaging instrument aligned with executive policy, not a legislative mandate.
What the text implies
- Resolution endorses executive action without legislative authorization—affirms Trump's May 2025 executive order but does not grant new statutory authority or funding, leaving implementation details to executive discretion.
- Most-favored-nation pricing may face legal challenge from pharmaceutical manufacturers on constitutional grounds (takings clause, due process); resolution does not address implementation barriers or litigation risk.
- Bipartisan framing masks potential disagreement on mechanism: Medicare negotiation (already law under IRA 2022) vs. price-control models that may require new legislation or regulatory authority not yet granted.
- Resolution cites HHS/RAND 2024 study and Kaiser polling but does not specify which 'other developed nations' or how price-alignment would be enforced, leaving substantive policy design to future rulemaking.
Who it affects
Ordinary Americans pay significantly more for prescription drugs than citizens in comparable countries. A policy aligning U.S. prices with international lows would reduce out-of-pocket costs for patients, address documented barriers to medication access (21% skip prescriptions due to cost), and expand affordability. The resolution supports both price-alignment mechanisms and Medicare negotiation expansion.
Who stands to gain
- U.S. patients and consumers (reduced out-of-pocket drug costs)
- Medicare and Medicaid (lower drug expenditures)
- Employers and insurers (reduced pharmacy benefit costs)
Named in the bill
Department of Health and Human Services, RAND Health Care, Organization for Economic Cooperation and Development, Kaiser Family Foundation, President Trump, Pharmaceutical manufacturers, Medicare, Medicaid
Where it stands
1 cosponsor: 1 Republicans.
- Dec 4, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 5, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress backs drug price cap tied to lowest international rates” QuorumCivic. https://share.quorumcivic.app/bill/119/hres928 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.